


10/525121
BT01 Rec'd PCT/PTC 18 FEB 2005

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I):



wherein:

- R¹ is C₁₋₆ alkoxy; (optionally substituted by C₁₋₄ alkoxy or phenyl); C₃₋₆ alkenyloxy, phenoxy or piperidin-4-yl; (1-substituted by C(O)R⁷ or S(O)₂R⁸);
- R² is optionally substituted phenyl, optionally substituted heteroaryl or cycloalkyl;
- R^{2a}, R⁴ and R^{4a} are, independently, hydrogen or C₁₋₄ alkyl;
- R³ and R^{3a} are, independently, hydrogen or C₁₋₄ alkyl or C₁₋₄ alkoxy;
- R⁵ is hydrogen, C₁₋₄ alkyl; (optionally substituted by halogen, hydroxy, C₁₋₄ alkoxy, C₃₋₇ cycloalkyl, SH, C₁₋₄ alkylthio, cyano or S(O)_q(C₁₋₄ alkyl)); C₃₋₄ alkenyl, C₃₋₄ alkynyl or C₃₋₇ cycloalkyl;
- R⁶ is phenyl, heteroaryl, phenylNH, heteroarylNH, phenyl(C₁₋₂)alkyl, heteroaryl(C₁₋₂)alkyl, phenyl(C₁₋₂ alkyl)NH or heteroaryl(C₁₋₂ alkyl)NH;
- R⁷ is C₁₋₆ alkyl; (optionally substituted by phenyl, heteroaryl, C₁₋₄ alkoxy, or C₁₋₄ alkoxy(C₁₋₄ alkoxy)); C₁₋₆ alkoxy, phenyl, heteroaryl or C₃₋₆ cycloalkyl;
- R⁸ is C₁₋₆ alkyl; (optionally substituted by phenyl); or phenyl;


wherein the phenyl and heteroaryl rings of any of the foregoing are independently optionally substituted by halo, cyano, nitro, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(O)_mC₁₋₄ alkyl, S(O)₂NR⁹R¹⁰, NHS(O)₂(C₁₋₄ alkyl), NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, NHC(O)NH₂, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃, CHF₂, CH₂F, CH₂CF₃ or OCF₃;
R⁹ and R¹⁰ are, independently, hydrogen or C₁₋₄ alkyl, or together with a nitrogen or oxygen atom, may join to form a 5- or 6-membered ring which is optionally substituted with C₁₋₄ alkyl, C(O)H or C(O)(C₁₋₄ alkyl);
m, p and q are, independently, 0, 1 or 2;
or a pharmaceutically acceptable salt thereof or a solvate thereof.

2. (Currently amended) A compound as claimed in claim 1 wherein R¹ is piperidin-4-yl 1-substituted by C(O)R⁷; {wherein R⁷ is C₁₋₆ alkyl; {optionally mono-substituted by phenyl}; C₁₋₆ alkoxy, phenyl or C₃₋₆ cycloalkyl, wherein the phenyl rings are optionally substituted by halogen}; or S(O)₂R⁸; {wherein R⁸ is phenyl or C₁₋₆ alkyl; {optionally mono-substituted by phenyl}; wherein the phenyl rings are optionally substituted by halogen, S(O)₂(C₁₋₄ alkyl) or NHC(O)(C₁₋₄ alkyl)}; or R¹ is C₁₋₆ alkoxy; {optionally substituted by C₁₋₄ alkoxy or phenyl}; C₃₋₆ alkenyloxy or phenoxy; {optionally substituted by halogen}.
3. (Currently amended) A compound as claimed in claim 1 ~~or 2~~ wherein R² is phenyl optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(O)_n(C₁₋₄ alkyl); {wherein n is 0, 1 or 2}; nitro, cyano or CF₃.
4. (Currently amended) A compound as claimed in claim 1, ~~2 or 3~~ wherein R^{2a}, R³, R^{3a}, R⁴ and R^{4a} are all hydrogen.
5. (Currently amended) A compound as claimed in claim 1, ~~2, 3 or 4~~ wherein R⁵ is ethyl.

6. (Currently amended) A compound as claimed in claim ~~1, 2, 3, 4 or 5~~ wherein R^6 is benzyl singly substituted by $S(O)_2(C_{1-4})$ alkyl or $S(O)_2NR^9R^{10}$; wherein R^9 and R^{10} are, independently, hydrogen or C_{1-4} alkyl, or together with a nitrogen or oxygen atom, may join to form a 5- or 6-membered ring which is optionally substituted with C_{1-4} alkyl, $C(O)H$ or $C(O)(C_{1-4}$ alkyl).

7. (Currently amended) A process for preparing a compound of claim 1, formula (I) comprising:

- a) treating a compound of formula (II):




with:

- i. an acid chloride or chloroformate of formula $R^1C(O)Cl$, in the presence of a base and in a suitable solvent; or
- ii. when R^1 is a 1-substituted piperidin-4-yl, an acid of formula R^1CO_2H in the presence of a suitable coupling agent in a suitable solvent;

OR

- b) reacting a compound of formula (VII):



- i. with an acid chloride $R^7C(O)Cl$ or sulfonyl chloride $R^8S(O)_2Cl$ in the presence of a base and in a suitable solvent; or
 - ii. with an acid of formula R^7CO_2H in the presence of a suitable coupling agent in the presence of a suitable base in a suitable solvent.
- 8. (Original) A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 9-10. (Cancelled)
- 11. (Currently amended) A method of treating a chemokine mediated disease state ~~in a warm blooded animal suffering from, or at risk of, said disease, which comprises, comprising~~ administering ~~to an animal in need of such treatment a therapeutically effective amount~~ of a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1.